J&J, Idor­sia build out piv­otal dataset for their $230M hy­per­ten­sion drug, show­ing a main­tained re­sponse

J&J and Idor­sia pre­sent­ed new Phase III da­ta for their hy­per­ten­sion drug Tues­day morn­ing.

The tri­al found that aproci­ten­tan, the drug in ques­tion, re­duced blood pres­sure by a sta­tis­ti­cal­ly sig­nif­i­cant mar­gin and main­tained its ef­fect for up to 48 weeks, the com­pa­nies said. Re­searchers were test­ing aproci­ten­tan in pa­tients whose high blood pres­sure is tough to con­trol and in com­bi­na­tion with stan­dard back­ground ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER